New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:33 EDTFMS, MNKMallinckrodt raised Ofirmev price by 140%, says Piper Jaffray
Piper Jaffray says that according to Price Rx, Mallinckrodt (MNK) implemented a 140% price increase for Ofirmev on May 15. Piper views the increase as larger than expected and says it significantly reduces the risk to shares should Fresenius (FMS) launch its Ofirmev generic over the next two years. Piper thinks the risk/reward on shares of Mallinckrodt is compelling and it reiterates an Overweight rating on the stock.
News For MNK;FMS From The Last 14 Days
Check below for free stories on MNK;FMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
13:23 EDTFMSGoldman to hold a conference
Subscribe for More Information
August 28, 2014
09:03 EDTMNKMallinckrodt to present data on MNK-155, XARTEMIS XR at PAINWeek
Subscribe for More Information
August 25, 2014
10:40 EDTMNKBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 22, 2014
09:02 EDTMNKMallinckrodt names Furey Chief Compliance Officer
Subscribe for More Information
August 21, 2014
15:16 EDTMNKDEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
August 19, 2014
09:21 EDTMNKMallinckrodt now a component of the S&P 500 Index
The inclusion comes following the completion of Mallinckrodt’s acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company’s balance sheet, cash generation and leverage position.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use